Zobrazeno 1 - 10
of 421
pro vyhledávání: '"F. H. Top"'
Autor:
Lv, Ya-Nan1 (AUTHOR), Zeng, Mei1 (AUTHOR), Yan, Zi-Yu1 (AUTHOR), Zhang, Pei-Yan1 (AUTHOR), Ban, Ning1 (AUTHOR), Yuan, Dong-Wei1 (AUTHOR), Li, Sheng1,2 (AUTHOR) lisheng@scnu.edu.cn, Luan, Yun-Xia1,2 (AUTHOR) yxluan@scnu.edu.cn, Bai, Yu1,2 (AUTHOR) yubai@m.scnu.edu.cn
Publikováno v:
BMC Biology. 10/11/2024, Vol. 22 Issue 1, p1-13. 13p.
Autor:
Han, Dong‐Yeob1 (AUTHOR), Kim, Saehun2 (AUTHOR), Nam, Seoha1 (AUTHOR), Lee, Gayoung3 (AUTHOR), Bae, Hongyeul4 (AUTHOR), Kim, Jin Hong4 (AUTHOR), Choi, Nam‐Soon2 (AUTHOR), Song, Gyujin5 (AUTHOR) gyujin.song@kier.re.kr, Park, Soojin1,3 (AUTHOR) soojin.park@postech.ac.kr
Publikováno v:
Advanced Science. 7/3/2024, Vol. 11 Issue 25, p1-13. 13p.
Publikováno v:
Journal - Michigan State Medical Society. 45
Autor:
F H, TOP
Publikováno v:
The Illinois medical journal. 92(5)
Autor:
E T, WILLIAMS, F H, TOP
Publikováno v:
Proceedings. American Federation for Clinical Research. 2
Autor:
E A, Simoes, H M, Sondheimer, F H, Top, H C, Meissner, R C, Welliver, A A, Kramer, J R, Groothuis
Publikováno v:
The Journal of pediatrics. 133(4)
To examine the effectiveness of respiratory syncytial virus immune globulin administered intravenously (RSV-IGIV) in reducing hospitalization for treatment of RSV in children with congenital heart disease (CHD).Children younger than 4 years of age we
Autor:
X, Sáez-Llorens, E, Castaño, D, Null, J, Steichen, P J, Sánchez, O, Ramilo, F H, Top, E, Connor
Publikováno v:
The Pediatric infectious disease journal. 17(9)
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory disease in infants and children. MEDI-493 (palivizumab, Synagis) is a humanized monoclonal IgG1 antibody to the fusion protein of RSV, and it is highly active in vitro agains
Autor:
Kurniawati, Ischia1 (AUTHOR) chnj@gnu.ac.kr, Sung, Yonmo2 (AUTHOR) ysung@gnu.ac.kr
Publikováno v:
Energies (19961073). Apr2024, Vol. 17 Issue 7, p1721. 30p.
Publikováno v:
PEDIATRICS. 100:275-275
To the Editor. The publication of the PREVENT trial allows the first opportunity to critically analyze data used by the Food and Drug Administration over 1 year ago to approve RespiGam for reducing the incidence and duration of respiratory syncytial
Autor:
Caddeo, Francesco1,2,3 (AUTHOR), Himmelstein, Florian1,2 (AUTHOR), Mahmoudi, Behzad1,2 (AUTHOR), Araújo-Cordero, Ana María1,2 (AUTHOR), Eberhart, Denis1,2 (AUTHOR), Zhang, Haojie1,4,5 (AUTHOR), Lindenberg, Titus1,2 (AUTHOR), Hähnel, Angelika6 (AUTHOR), Hagendorf, Christian6 (AUTHOR), Maijenburg, A. Wouter1,2 (AUTHOR) wouter.maijenburg@chemie.uni-halle.de
Publikováno v:
Scientific Reports. 11/20/2023, Vol. 13 Issue 1, p1-10. 10p.